A network of experts in reproductive and children’s environmental health

Marijuana > Marijuana Use in Perinatal Populations

Marijuana Use in Perinatal Populations

posted on Aug 4, 2017
This course qualifies as continuing education for physicians, nurses, certified health education specialists and other professionals provided by the Centers for Disease Control and its partners.

Origination Date – 06/30/2017
Expiration Date – 06/30/2019

The goal of this course is to enhance the knowledge of physicians and other healthcare providers about marijuana perceptions and usage among perinatal populations. This module will also discuss the prevalence and long-term impacts marijuana usage may have on pregnant women and their children. By enhancing their knowledge, physicians and other healthcare providers can better assess patients who use marijuana and provide informed guidance to their patients regarding marijuana use.

Learning Objectives:

  1. Recognize the basic pharmacology, pharmacokinetics, and methods of marijuana use
  2. Explain marijuana urine testing
  3. Describe the prevalence of marijuana use among perinatal populations
  4. Describe the long-term impacts marijuana may have on pregnant women and the neonate
  5. Identify strategies for communicating risk and providing guidance to pregnant patients

Developed By:

Wang_Sam125

George Sam Wang, MD, FAAP
Assistant Professor of Pediatrics
Section of Emergency Medicine, Medical Toxicology
Department of Pediatrics
University of Colorado Anschutz Medical Campus, Children's Hospital Colorado
Aurora, CO
 
Dr. Wang, completed his pediatric residency and pediatric emergency medicine fellowship at Children's Hospital Colorado/Anschutz Medical Campus, and his medical toxicology fellowship at the Rocky Mountain Poison and Drug Center at Denver Health. He is an Assistant Professor of Pediatrics at Children's Hospital Colorado/Anschutz Medical Campus where he is a PEM and toxicology attending.  

This material was supported by the American College of Medical Toxicology (ACMT) and funded (in part) by the cooperative agreement FAIN: U61TS000238-03 from the Agency for Toxic Substances and Disease Registry (ATSDR).

Acknowledgement: The U.S. Environmental Protection Agency (EPA) supports the PEHSU by providing partial funding to ATSDR under Inter-Agency Agreement number DW-75-95877701. Neither EPA nor ATSDR endorse the purchase of any commercial products or services mentioned in PEHSU publications.

 
Take_Course_Button.png
Filed under: Marijuana